Related Experiment Videos
Nomifensine in parkinsonism
Journal of Neurology, Neurosurgery, and Psychiatry
|December 1, 1976
Abstract:
Nomifensine, a tetrahydroisoquinolone antidepressant which facilitates dopaminergic and noradrenergic transmission, was studied in 28 Parkinsonism patients most of whom were also receiving conventional medications. Double-blind evaluations revealed a moderate therapeutic action at a mean dose level of 150 mg daily. Adverse reactions were encountered, similar to those identical by levodopa.
Insights
Nomifensine, an antidepressant, showed moderate therapeutic effects in Parkinsonism patients by enhancing dopamine and norepinephrine. Adverse reactions were observed, similar to levodopa treatments.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Neurology
Background:
- Parkinsonism is a complex neurological disorder.
- Current treatments like levodopa have limitations and side effects.
- Dopaminergic and noradrenergic pathways are implicated in Parkinsonism.
Purpose of the Study:
- To evaluate the efficacy and safety of nomifensine in Parkinsonism patients.
- To assess nomifensine's impact on dopaminergic and noradrenergic transmission in this patient group.
Main Methods:
- A double-blind evaluation was conducted on 28 Parkinsonism patients.
- Most patients were on conventional Parkinsonism medications.
- Nomifensine was administered at a mean daily dose of 150 mg.
Main Results:
- Nomifensine demonstrated a moderate therapeutic effect in Parkinsonism.
- The mean effective daily dose was 150 mg.
- Adverse reactions were reported, comparable to those seen with levodopa.
Conclusions:
- Nomifensine exhibits potential as a treatment for Parkinsonism.
- Further research is warranted to explore its therapeutic profile and side effect management.
- The drug's action on neurotransmitter systems may offer an alternative therapeutic strategy.